BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 29762727)

  • 1. Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.
    Saito M; Shiraishi K; Goto A; Suzuki H; Kohno T; Kono K
    Jpn J Clin Oncol; 2018 Jul; 48(7):603-608. PubMed ID: 29762727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.
    Saito M; Suzuki H; Kono K; Takenoshita S; Kohno T
    Surg Today; 2018 Jan; 48(1):1-8. PubMed ID: 28280984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
    Gadgeel SM
    Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unravelling the biology of SCLC: implications for therapy.
    Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
    Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
    Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line treatments of small-cell lung cancers.
    Baize N; Monnet I; Greillier L; Quere G; Kerjouan M; Janicot H; Vergnenegre A; Auliac JB; Chouaid C
    Expert Rev Anticancer Ther; 2017 Nov; 17(11):1033-1043. PubMed ID: 28849951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SCLC-State of the Art and What Does the Future Have in Store?
    Kahnert K; Kauffmann-Guerrero D; Huber RM
    Clin Lung Cancer; 2016 Sep; 17(5):325-333. PubMed ID: 27397481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical Development of Immunotherapy for Small Cell Lung Cancer].
    Yu T; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):918-923. PubMed ID: 30591100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new hope: the immunotherapy in small cell lung cancer.
    Li Q; Yuan D; Ma C; Liu Y; Ma L; Lv T; Song Y
    Neoplasma; 2016; 63(3):342-50. PubMed ID: 26925794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future therapeutic approaches for the treatment of small cell lung cancer.
    Rossi A; Tay R; Chiramel J; Prelaj A; Califano R
    Expert Rev Anticancer Ther; 2018 May; 18(5):473-486. PubMed ID: 29544351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer.
    Saito M; Saito K; Shiraishi K; Maeda D; Suzuki H; Minamiya Y; Kono K; Kohno T; Goto A
    Mol Clin Oncol; 2018 Feb; 8(2):310-314. PubMed ID: 29435295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunotherapy Advances in Small Cell Lung Cancer].
    Xu Y; Zhan P; Song Y
    Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):989-998. PubMed ID: 32752583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer.
    Yu L; Lai Q; Gou L; Feng J; Yang J
    J Drug Target; 2021 Jan; 29(1):1-11. PubMed ID: 32700566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for small-cell lung cancer: emerging evidence.
    Reck M; Heigener D; Reinmuth N
    Future Oncol; 2016 Apr; 12(7):931-43. PubMed ID: 26882955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
    Gelsomino F; Lamberti G; Parisi C; Casolari L; Melotti B; Sperandi F; Ardizzoni A
    Cancer Treat Rev; 2019 Sep; 79():101887. PubMed ID: 31491661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer].
    Huang B; Duan Y
    Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):239-244. PubMed ID: 31014443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Origins, genetic landscape, and emerging therapies of small cell lung cancer.
    Semenova EA; Nagel R; Berns A
    Genes Dev; 2015 Jul; 29(14):1447-62. PubMed ID: 26220992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects of targeted and immune therapies in SCLC.
    Hendriks LEL; Menis J; Reck M
    Expert Rev Anticancer Ther; 2019 Feb; 19(2):151-167. PubMed ID: 30590971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.